10-Q: LAVA Therapeutics Q3 2025: XOMA Acquisition Progresses Amid Program Wind-Down

LAVA Therapeutics N.V. reported Q3 2025 results, highlighting progress on its acquisition by XOMA Royalty Corporation, significant workforce reductions, and the discontinuation of clinical programs LAVA-1207 and LAVA-1266.

Summary

• LAVA Therapeutics N.V. is being acquired by XOMA Royalty Corporation for $1.04 cash per share plus one Contingent Value Right (CVR).
• The CVR provides potential future cash payments from excess closing net cash, disposition of LAVA-1266 assets, proceeds from Pfizer and J&J collaborations, and a tax reserve matter.
• The minimum Closing Net Cash condition for the acquisition was reduced from $31.5 million to $24.5 million.
• The tender offer expiration was extended to November 12, 2025, and an Extraordinary General Meeting (EGM) is reconvening on November 7, 2025.
• The company implemented a restructuring plan, reducing its workforce by approximately 71% to 10 full-time employees as of September 30, 2025.
• Clinical programs LAVA-1207 (prostate cancer) and LAVA-1266 (AML/MDS) have been discontinued, with the company winding down all clinical and nonclinical research and development activities.
• Net loss for the nine months ended September 30, 2025, was $19.306 million, compared to $21.237 million for the same period in 2024.
• Research and development expenses decreased significantly to $11.134 million for the nine months ended September 30, 2025, from $19.881 million in 2024, due to program discontinuations.
• General and administrative expenses increased to $11.296 million for the nine months ended September 30, 2025, from $9.881 million in 2024, primarily due to XOMA transaction-related legal and professional fees.
• The company recognized a $5.203 million gain on extinguishment of borrowings in March 2025 due to the permanent waiver of a $5.2 million Innovation Credit loan from Rijksdienst voor Ondernemend Nederland (RVO).
• Cash and cash equivalents stood at $49.664 million as of September 30, 2025, up from $35.015 million at December 31, 2024.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While the XOMA acquisition provides an exit, the terms are modest ($1.04 cash per share) and the CVR is highly contingent, carrying significant risk of expiring valueless. The company is winding down its core operations, discontinuing clinical programs, and has incurred substantial losses, reflecting a failure of its independent drug development strategy. The increase in cash is primarily from investment maturities, not operational success. The future is entirely dependent on the XOMA deal closing, which itself has risks and has already seen delays.

Positives

• The XOMA acquisition provides a clear exit strategy for shareholders, offering $1.04 cash per share plus a Contingent Value Right (CVR).
• The reduction in the minimum Closing Net Cash condition from $31.5 million to $24.5 million increases the likelihood of the XOMA transaction closing.
• The company recognized a $5.203 million gain from the permanent waiver of a loan from RVO, improving its financial position.
• Significant reductions in research and development expenses (down $8.747 million year-over-year for nine months) due to program discontinuations are preserving capital.
• Cash and cash equivalents increased to $49.664 million as of September 30, 2025, from $35.015 million at December 31, 2024, partly due to maturities of investments.

Negatives

• The company reported no revenue from contracts with customers for the nine months ended September 30, 2025, a significant decrease from $6.992 million in the prior year.
• Net loss for the nine months ended September 30, 2025, was $19.306 million, indicating continued unprofitability.
• General and administrative expenses increased by $1.415 million for the nine months ended September 30, 2025, primarily due to legal and professional fees associated with the XOMA transaction.
• Foreign currency exchange loss, net, increased significantly to $3.504 million for the nine months ended September 30, 2025, from $0.722 million in 2024.
• The company's future operations are highly dependent on the successful consummation of the XOMA Transaction, with no assurances it will close.
• The discontinuation of LAVA-1207 and LAVA-1266 programs signifies the end of the company's proprietary drug development efforts.
• The CVRs are contingent and may expire valueless if specific milestones or proceeds are not achieved within the defined timeframes.

Risks

• The XOMA Transaction is subject to conditions, including a minimum tender condition (at least 80%, or 75% in certain cases, of shares tendered) and a Closing Net Cash Condition of at least $24.5 million, which may not be satisfied.
• Failure to complete the XOMA Transaction could have a material adverse effect on the business, operating results, financial condition, and share price, and the company would remain liable for significant transaction costs.
• Additional extensions of the tender offer period would further deplete cash and cash equivalents, potentially compromising the ability to meet the Closing Net Cash Condition.
• Shareholders may not receive any payment on the CVRs, and they may expire valueless, as payments are contingent on future events like asset dispositions or collaboration proceeds.
• The Purchase Agreement contains provisions (e.g., non-solicitation, termination fee of $0.75 million) that could discourage competing acquirers or result in a lower acquisition price.
• Shareholder or other litigation (including creditor opposition under Dutch law) could prevent or delay the consummation of the XOMA Transaction or negatively impact the business.
• The announcement and pendency of the XOMA Transaction could adversely affect the business, financial results, and operations, including challenges in employee retention and diversion of management's attention.
• The company is subject to contractual restrictions during the pendency of the XOMA Transaction, limiting its ability to pursue attractive business opportunities without XOMA's consent.
• If the XOMA Transaction is not consummated, the board may pursue dissolution and liquidation, where the amount of cash available for distribution to shareholders would depend on timing and reserves for obligations, potentially leading to shareholders losing all or a significant portion of their investment.

Future Outlook

The company's future operations are highly dependent on the successful consummation of the XOMA Transaction, which is expected to close in the fourth quarter of 2025. If the transaction fails, the company may explore other strategic alternatives, including dissolution and liquidation. The company anticipates a continued decrease in research and development expenses as it winds down all clinical and nonclinical programs. General and administrative expenses may increase in the short term due to ongoing XOMA transaction costs. Management believes current cash and cash equivalents are sufficient to fund planned expenditures for at least the next twelve months, assuming the XOMA transaction proceeds as planned.

Management Comments

• Management expects to incur additional losses in the foreseeable future.
• Management expects the XOMA Transaction to close in the fourth quarter of 2025.
• Management believes that cash and cash equivalents will be sufficient to fund planned expenditures and meet obligations for at least the next twelve months from the issuance date of the condensed consolidated financial statements.

Industry Context

LAVA Therapeutics' situation reflects a common trend in the biotech industry where smaller, clinical-stage companies, especially those facing significant R&D costs and limited pipeline success, seek strategic alternatives like acquisition. The acquisition by XOMA Royalty Corporation, a company focused on acquiring royalty streams, indicates a shift from active drug development to monetizing existing intellectual property and collaboration agreements. The discontinuation of proprietary clinical programs (LAVA-1207, LAVA-1266) aligns with a strategic pivot away from direct drug development, a move often seen when a company's internal benchmarks are not met or capital resources are constrained. The continued collaboration with larger pharmaceutical partners like Pfizer and Johnson & Johnson, whose milestones contribute to the CVR, highlights the value of early-stage assets even when the originating company ceases independent development.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results for direct assessment against industry standards. The company is undergoing an acquisition and winding down its proprietary programs, making direct performance comparisons less relevant than the terms of the acquisition and CVR.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently subject to any material legal proceedings as of September 30, 2025 or December 31, 2024.

Related Party Transactions

• No new material related party dealings were disclosed in the filing.

Stakeholder Impact

• Shareholders: Will receive $1.04 cash per share plus a contingent CVR if the XOMA transaction closes. The value of the CVR is uncertain and could be zero. If the deal fails, they face potential dissolution and liquidation with uncertain returns.
• Employees: Workforce significantly reduced by approximately 71% to 10 full-time employees. Remaining employees are essential for SEC reporting and value realization for the XOMA transaction. Uncertainty about roles and potential severance payments are noted.
• Customers/Partners (Pfizer, J&J): Collaborations continue, with potential future proceeds contributing to CVRs. The company's direct R&D efforts are ceasing, but partnered programs are still advancing.
• Creditors: The $5.2 million RVO loan was waived, reducing liabilities. Other obligations will need to be paid or reserved for, especially in a liquidation scenario.
• Suppliers: Contracts have been terminated as part of the restructuring, leading to associated costs.

Next Steps

• Shareholders to vote at the reconvened Extraordinary General Meeting (EGM) on November 7, 2025, regarding the XOMA transaction.
• Tender offer for XOMA acquisition to expire on November 12, 2025 (unless further extended or terminated).
• Completion of the XOMA Transaction, expected in the fourth quarter of 2025.
• Continued wind-down of all clinical and nonclinical research and development activities.
• If the XOMA Transaction is not consummated, the company may explore other strategic alternatives, including dissolution and liquidation.

Key Dates

Recommendation

The company is in the process of being acquired by XOMA Royalty Corporation, offering a fixed cash price of $1.04 per share plus a Contingent Value Right (CVR). For existing shareholders, the primary decision revolves around tendering shares for the cash and CVR, or holding out for a potentially higher, but unlikely, alternative offer, or facing the risk of dissolution if the XOMA deal fails. Given the company is winding down its operations and has discontinued its clinical programs, its standalone value proposition is minimal. The CVR's value is highly speculative and contingent on future events, making it difficult to price. The 'hold' recommendation is for shareholders to await the tender offer's conclusion, as the current share price likely reflects the acquisition terms. A 'sell' could be considered if an investor wishes to avoid the CVR's uncertainty and the remaining risks of the deal not closing, but the current market price already incorporates much of this information. A 'buy' is not justified as the company's independent operations are ceasing, and the upside is capped by the acquisition price plus a highly uncertain CVR.

Keywords

LAVA Therapeutics, LVTX, XOMA Royalty Corporation, Acquisition, Tender Offer, Contingent Value Right, CVR, Biotechnology, Immuno-oncology, Clinical-stage, Drug Development, Restructuring, Clinical Trials, LAVA-1207, LAVA-1266, Pfizer Collaboration, Johnson & Johnson Collaboration, Financial Results, SEC Filing, 10-Q